Cargando…
Prognostic tools at hospital arrival in acute myocardial infarction: copeptin and hepatocyte growth factor
BACKGROUND: Prompt evaluation and treatment of acute coronary syndrome has demonstrated to reduce mortality. Although several biomarkers have been studied for risk stratification and prognostic purposes, none is recommended to guide treatment based on its prognostic value. Copeptin and hepatocyte gr...
Autores principales: | Pintado, María-Consuelo, Maceda, Lara, Trascasa, María, Arribas, Ignacio, De Pablo, Raúl |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9050999/ https://www.ncbi.nlm.nih.gov/pubmed/35482134 http://dx.doi.org/10.1186/s43044-022-00275-9 |
Ejemplares similares
-
Copeptin—Marker of Acute Myocardial Infarction
por: Möckel, Martin, et al.
Publicado: (2014) -
Copeptin Testing in Acute Myocardial Infarction: Ready for Routine Use?
por: Reinstadler, Sebastian Johannes, et al.
Publicado: (2015) -
Comparison of the temporal release pattern of copeptin with conventional biomarkers in acute myocardial infarction
por: Gu, Youlan L., et al.
Publicado: (2011) -
Performance of Copeptin for Early Diagnosis of Acute Myocardial Infarction in an Emergency Department Setting
por: Jeong, Ji Hun, et al.
Publicado: (2020) -
Prognostic value of copeptin in patients with acute myocardial infarction treated with percutaneous coronary intervention: a prospective cohort study
por: Roczek-Janowska, Marta, et al.
Publicado: (2021)